Search Articles — Sudonull

Search Results

In this project

Multilayer architecture: sublayers and data models

https://sudonull.com/multilayer-architecture-sublayers-and-data-models

Breakdown of multilayer application architecture for middle/senior developers: layers, sublayers, dataflow. Examples for web-services and report viewer. Study the hierarchy for scalable systems.

Web Application Vulnerabilities: XSS SQLi enumeration

https://sudonull.com/web-application-vulnerabilities-xss-sqli-enumeration

Breakdown of top-3 vulnerabilities in web: user enumeration, XSS, SQL injections. Fix methods for developers: prepared statements, encoding. In-depth pentest guide.

How to Design a Scalable Web Application Architecture

https://sudonull.com/how-to-design-a-scalable-web-application-architecture

Learn how to design a scalable web application architecture with practical strategies for statelessness, database sharding, caching, and observability. Expert guide with actionable steps.

From bot to web-system: Excel automation

https://sudonull.com/from-bot-to-web-system-excel-automation

Learn how to turn a Telegram bot into a scalable web application for Excel processing. Saving 150 hours/month, architecture, AI in development. Instructions for developers.

From other projects

Pediatric Dovato: EMA Approves Application for HIV Therapy

https://ymaho.com/pediatric-dovato-ema-approves-application-for-hiv-therapy

EMA validated the application for pediatric Dovato (dolutegravir/lamivudine) for children from 2 years old. Learn how two-drug therapy is changing HIV treatment standards.

EMA accepted the application for Dovato for children with HIV

https://ymaho.com/ema-accepted-the-application-for-dovato-for-children-with-hiv

EMA validated the application for the use of Dovato in children from 3 months with HIV. Learn how this will change pediatric therapy and strengthen ViiV's position. Read the detailed analysis.

Study of the Ottava robot: FORTE results and FDA application

https://ymaho.com/study-of-the-ottava-robot-forte-results-and-fda-application

Scientists have completed the pivotal study of the Ottava robot (FORTE) and are preparing an FDA application. Learn about clinical data, zero conversions, and market prospects for robotic surgery.

Gene therapy for deafness otarmeni EMA: accelerated review 2026

https://ymaho.com/gene-therapy-for-deafness-otarmeni-ema-accelerated-review-2026

EMA accepted the application for gene therapy otarmeni for the treatment of hereditary deafness OTOF. Market analysis, forecasts, price and implications for the industry. Read.

SpaceX IPO: filing for $75 billion and valuation of $1.75 trillion

https://ymaho.com/spacex-ipo-filing-for-75-billion-and-valuation-of-1-75-trillion

SpaceX filed an application for the largest IPO in history on Nasdaq up to $75 billion. Valuation $1.75 trillion, listing in June 2026. Analysis of the record, consequences and hidden details. Read more.

Intellia CRISPR therapy: FDA filing for lonvo-z for HAE

https://ymaho.com/intellia-crispr-therapy-fda-filing-for-lonvo-z-for-hae

Intellia has filed the world's first application for an in vivo CRISPR therapy, lonvo-z, for hereditary angioedema (HAE). 87% reduction in attacks, 62% attack-free. Risk, market, and forecast analysis. Read.

From the web

El Diario de Atacama

https://www.diarioatacama.cl/

Opinión | Pág. 7 Correo Actualidad | Pág. 2 VIF marca parte de la demanda en las urgencias de Atacama: 160 atenciones Reportajes …

Vacunación Covid-19

https://www.diarioatacama.cl/especiales/vacunacion/

El Diario de Atacama

Trending Now